{"id":969778,"date":"2026-06-02T17:01:13","date_gmt":"2026-06-02T21:01:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/"},"modified":"2026-06-02T17:01:13","modified_gmt":"2026-06-02T21:01:13","slug":"fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/","title":{"rendered":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, June 2, 2026<\/span> \/PRNewswire\/ — Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review. Shareholders who lost money on FULC are encouraged to submit their information now<\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>\n

\n

\n
\n \"Levi
\n <\/a>\n <\/p>\n<\/p><\/div>\n

During the Q1 2026 earnings call on April 27, 2026, CEO Alex Sapir stated the company believed it had “about a 24-month head start over the next closest competitor” and would be “well underway, we believe, with our Phase III study.” The company’s 10-K filed February 24, 2026 disclosed a lease with a total commitment of approximately $25.1 million over its 10-year term covering 28,731 square feet of office and laboratory space. The Company’s CAMP4 license agreement provided for up to $70 million in milestone payments plus royalties, while the upfront payment amount remained undisclosed.<\/p>\n

Approximately five weeks after the Q1 2026 earnings call, Fulcrum discontinued the pociredir program following FDA feedback indicating no regulatory path forward and initiated strategic review. The company’s existing ~$25.1 million long-term lease obligation and the CAMP4 licensing agreement\u2014providing up to $70 million in milestones plus royalties with an undisclosed upfront payment\u2014remained in place. Following the discontinuation, Fulcrum entered strategic review without a lead clinical candidate. Levi & Korsinsky is investigating whether these forward commitments and omissions may constitute potential securities law violations.<\/p>\n

Those who purchased FULC and wish to discuss their legal rights may click here to get started<\/a>. You may also reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>\n

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com<\/a><\/p>\n

Frequently Asked Questions About the FULC Investigation<\/p>\n

\n Q: How much did FULC stock drop?<\/b>A: Shares fell approximately 50% in a single session after Fulcrum Therapeutics disclosed FDA safety concerns that forced immediate discontinuation of pociredir and launch of a strategic review.<\/p>\n

\n Q: Which statements are being investigated as potentially misleading?<\/b>A: The investigation concerns whether Fulcrum Therapeutics made materially false or misleading statements regarding the forward outlook for pociredir, including Phase III timelines and competitive positioning, while simultaneously maintaining existing long-term financial commitments, including lease and licensing arrangements. When the program was discontinued, the stock declined sharply.<\/p>\n

\n Q: What do FULC investors need to do right now?<\/b>A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n

\n Q: What does it cost me to participate?<\/b>A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>\n

\n Q: What if I already sold my FULC shares — can I still recover losses?<\/b>A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought FULC and sold at a loss may still participate in the investigation.<\/p>\n

\n Q: Do I need to go to court or give testimony?<\/b>A: No. Participating in the investigation does not require court appearances or depositions.<\/p>\n

\n Q: What if I live outside the United States?<\/b>A: U.S. securities fraud<\/span><\/span> investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.<\/p>\n

CONTACT:\\<\/p>\n

Levi & Korsinsky, LLP\\<\/p>\n

Joseph E. Levi, Esq.\\<\/p>\n

Ed Korsinsky, Esq.\\<\/p>\n

33 Whitehall Street, 27th Floor\\<\/p>\n

New York, NY 10004\\<\/p>\n

\n jlevi@levikorsinsky.com<\/a>\\<\/p>\n

Tel: (212) 363-7500\\<\/p>\n

Fax: (212) 363-7171<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/fulcrum-therapeutics-inc-investigation-initiated-levi–korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc-302789096.html<\/a><\/p>\n

SOURCE Levi & Korsinsky, LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW YORK, June 2, 2026 \/PRNewswire\/ — Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review. Shareholders who lost money on FULC are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. During the Q1 2026 earnings call on April 27, 2026, CEO Alex Sapir stated the company believed it had “about a 24-month head … <\/p>\n

Continue reading “Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-969778","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW YORK, June 2, 2026 \/PRNewswire\/ — Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review. Shareholders who lost money on FULC are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. During the Q1 2026 earnings call on April 27, 2026, CEO Alex Sapir stated the company believed it had “about a 24-month head … Continue reading "Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T21:01:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)\",\"datePublished\":\"2026-06-02T21:01:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/\"},\"wordCount\":642,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/\",\"name\":\"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2026-06-02T21:01:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/","og_locale":"en_US","og_type":"article","og_title":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk","og_description":"PR Newswire Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW YORK, June 2, 2026 \/PRNewswire\/ — Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review. Shareholders who lost money on FULC are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. During the Q1 2026 earnings call on April 27, 2026, CEO Alex Sapir stated the company believed it had “about a 24-month head … Continue reading \"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-02T21:01:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)","datePublished":"2026-06-02T21:01:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/"},"wordCount":642,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/","name":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2026-06-02T21:01:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-inc-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=969778"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969778\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=969778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=969778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=969778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}